StockData
Viridian Therapeutics, Inc.\DE logo

Viridian Therapeutics, Inc.\DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Viridian Therapeutics, Inc.\DE r&d expenses

Research and development expenses are spending on new products and technology.

Viridian Therapeutics, Inc.\DE's R&D Expenses for the twelve months ending Jun 30, 2026 was $324.68M, up 6.6% year over year. For fiscal 2025 it was $338.93M, up 42.3% from the year before. Over ten years it grew 79.0% a year on average. The highest annual figure on record is $338.93M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$338.93M+42.3%
FY2024Dec 31, 2024$238.25M+49.1%
FY2023Dec 31, 2023$159.77M+58.3%
FY2022Dec 31, 2022$100.89M+77.4%
FY2021Dec 31, 2021$56.89M+101.0%
FY2020Dec 31, 2020$28.30M-18.7%
FY2019Dec 31, 2019$34.79M+14.4%
FY2018Dec 31, 2018$30.42M+55.0%
FY2017Dec 31, 2017$19.62M+43.3%
FY2016Dec 31, 2016$13.69M+1266.5%
FY2015Dec 31, 2015$1.00M+188.8%
FY2014Dec 31, 2014$347.00K+54.2%
FY2013Dec 31, 2013$225.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$71.58M-17.4%
Q1 FY2026Mar 31, 2026$77.63M+1.0%
Q4 FY2025Dec 31, 2025$89.21M+24.0%
Q3 FY2025Sep 30, 2025$86.26M+24.7%
Q2 FY2025Jun 30, 2025$86.63M+54.2%
Q1 FY2025Mar 31, 2025$76.84M+87.7%
Q4 FY2024Dec 31, 2024$71.96M+86.6%
Q3 FY2024Sep 30, 2024$69.16M+127.6%
Q2 FY2024Jun 30, 2024$56.19M+40.2%
Q1 FY2024Mar 31, 2024$40.94M-19.3%
Q4 FY2023Dec 31, 2023$38.56M-1.9%
Q3 FY2023Sep 30, 2023$30.39M+37.4%
Q2 FY2023Jun 30, 2023$40.08M+84.6%
Q1 FY2023Mar 31, 2023$50.74M+185.9%
Q4 FY2022Dec 31, 2022$39.32M+75.6%
Q3 FY2022Sep 30, 2022$22.12M+172.4%
Q2 FY2022Jun 30, 2022$21.71M+72.8%
Q1 FY2022Mar 31, 2022$17.75M+28.5%
Q4 FY2021Dec 31, 2021$22.39M+46.8%
Q3 FY2021Sep 30, 2021$8.12M+161.0%
Q2 FY2021Jun 30, 2021$12.57M+227.6%
Q1 FY2021Mar 31, 2021$13.81M+126.2%
Q4 FY2020Dec 31, 2020$15.25M+81.2%
Q3 FY2020Sep 30, 2020$3.11M-65.5%
Q2 FY2020Jun 30, 2020$3.84M-55.4%
Q1 FY2020Mar 31, 2020$6.10M-30.3%
Q4 FY2019Dec 31, 2019$8.42M+2.2%
Q3 FY2019Sep 30, 2019$9.03M+22.0%
Q2 FY2019Jun 30, 2019$8.60M+2.7%
Q1 FY2019Mar 31, 2019$8.75M+36.5%
Q4 FY2018Dec 31, 2018$8.23M+64.7%
Q3 FY2018Sep 30, 2018$7.40M+47.4%
Q2 FY2018Jun 30, 2018$8.38M+52.6%
Q1 FY2018Mar 31, 2018$6.41M+55.7%
Q4 FY2017Dec 31, 2017$5.00M+28.0%
Q3 FY2017Sep 30, 2017$5.02M+69.2%
Q2 FY2017Jun 30, 2017$5.49M–
Q1 FY2017Mar 31, 2017$4.12M–
Q4 FY2016Dec 31, 2016$3.91M–
Q3 FY2016Sep 30, 2016$2.97M–

More Viridian Therapeutics, Inc.\DE figures

See a number that looks wrong?